Top NYC Plastic Surgeon, Dr. Maurice Khosh, Named 2019 Best Doctor by Best Doctors in America®

NEW YORK, Nov. 12, 2019 /PRNewswire-PRWeb/ -- Each year, the Best Doctors in America organization awards a limited number of physicians with the honor of being selected as a Best Doctor. As the largest ongoing, peer-reviewed poll in the medical industry, the list is based on surveys of more than 53,000 medical experts in over 450 specialties and subspecialties worldwide. Dr. Maurice Khosh has been selected for this honor by his peers as a result of his extensive knowledge, artistic talent and exceptional skill in advanced facial plastic surgery. Dr. Khosh represents approximately 4% of U.S. doctors as a 2019 Best Doctor.

Dr. Maurice Khosh carries a unique set of dual board certifications in facial plastic surgery and ENT surgery. He is a highly respected plastic surgeon who has earned multiple prestigious awards for his advanced technique and beautiful, natural-looking results in cosmetic procedures, such as facelifts, rhinoplasty and blepharoplasty. Additionally, Dr. Khosh offers a wide range of reconstructive procedures to address functional, trauma or cancer-related defects of the face, nose and scalp. Dr. Khosh is also nationally recognized for his training and specialization in treating breathing issues during rhinoplasty. Beyond plastic surgery procedures, Dr. Khosh offers a full menu of non-invasive services, including rejuvenation treatments for the eyes, cheeks, lips and neck.

"I am honored that my colleagues have once again chosen me for inclusion on this prestigious list as a 2019 Best Doctor. It is a testament to my mission to provide my patients with high-quality care and excellence in facial plastic surgery," says Dr. Maurice Khosh

More About Proscia, a leading provider of digital pathology software, announces the Fall 2019 release of its Concentriq platform, along with a global collaboration with Dell Technologies, to help life sciences companies accelerate the adoption of digital pathology at an enterprise scale. Today's news includes significant product enhancements for more easily managing massive multi-site studies on the Concentriq platform, which is now optimized for cost, scale, and support with Dell Technologies' enterprise solutions.

Life sciences organizations have been on the forefront of digital pathology adoption in an effort to better incorporate pathology data into research and development. While they have amassed millions of images and volumes of associated clinical information, this data largely remains siloed, inaccessible, and dissociated from broader R&D efforts. Proscia introduced the Concentriq image and data management platform to help life sciences organizations adopt and scale digital pathology across the enterprise.

The Fall 2019 release extends Concentriq with new capabilities that drive consistency across pathology data for improved efficiency, visibility, and scalability. With this standardization, pharmaceutical, biotechnology, and contract research organizations (CROs) can streamline the launch and management of concurrent studies involving millions of images across multi-site, multi-role organizations.

The expanded Concentriq platform now provides:

• Scalable study management – New standard field libraries, templated projects, and expanded roles and permissions create a repeatable framework that simplifies study management and puts new control into the hands of IT administrators and project coordinators.
• Centralized pathology data management – Concentriq Workspaces offer a single pane of glass that presents data from multiple sources in a unified display, creating a center point of pathology research.
• Enhanced Global Search – Improved data consistency now enables global search across an entire organization's pathology data.
• Expanded Image Format Support – Zeiss CZI now joins Akoya Biosciences, Epredia, Hamamatsu, Huron, Leica, and VENTANA Roche as formats supported by Concentriq, allowing organizations to ingest images from a wide array of scanners to meet their specific needs.

"Digital pathology adoption among life sciences organizations is maturing, moving from point-level implementations to widescale rollouts transforming traditional practices across the enterprise," said Coleman Stavish, CTO, Proscia. "We delivered the Fall 2019 release of Concentriq to accelerate this adoption and support highly scalable, image-centric pathology, and our newly-formed collaboration with Dell Technologies furthers this aim."

To support the newly expanded Concentriq platform, Proscia has aligned with Dell Technologies to provide a cost-effective, scalable IT infrastructure for deploying digital pathology solutions. The companies worked together to provide reference architectures for whole-slide image viewing and management, including Proscia's Concentriq platform, combined with high performance compute, scalable storage, and Multi-Cloud capabilities from Dell Technologies. These reference architectures are designed for healthcare and life sciences organizations of any size that must meet today's requirements and anticipate the future needs of organizations as they scale.

"At Dell Technologies, we are committed to advancing the field of pathology with modern solutions to accelerate research breakthroughs and ultimately improve patient outcomes," said David DeAngelis, General Manager, Global Healthcare-Life Sciences, Dell Technologies. "Pathology is among the last fields in medicine to go digital. Together with Proscia, we are delivering the infrastructure and software that laboratories require for successful adoption of digital pathology."

To learn more about how healthcare and life sciences organizations are successfully managing research and development at scale with digital pathology, please join Proscia and Dell Technologies' upcoming webinar "Accelerate and Scale Enterprise Adoption of Digital Pathology" on Thursday, December 12 at 12PM ET.

Related resources:

• Concentriq Overview
• Blog: Accelerate Life Sciences R&D With Digital Pathology: Enhancements to Concentriq Make It Easier to Manage Massive, Multi-Site Studies
• Schedule a demo of Concentriq

About Proscia
Proscia is an AI software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company's Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries. Proscia's team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care. More information on Concentriq by Proscia can be found here. For more information about the company, visit proscia.com.

Dr. Maurice Khosh is a nationally recognized, dual board certified facial plastic surgeon practicing in Manhattan, NY. He has had a continued appearance on Castle Connolly's Top Doctor™ list and has been the recipient of the Patients' Choice Award. Dr. Khosh was also chosen as a 2019 Top Patient Rated NYC Plastic Surgeon by Find Local Doctors. He is the past president of the NY Facial Plastic Surgery Society, the director of facial plastic surgery service at Mt. Sinai West in NYC and the former director of facial plastic surgery at Columbia University. Dr. Maurice Khosh's dedication and expertise in his field have made him one of the top plastic and reconstructive surgeons in the country.

For more information on the services offered by Dr. Khosh, visit his website at http://www.facedoctornyc.com, or contact his office in Manhattan directly at (212) 339-9988.

SOURCE Maurice M. Khosh, MD, FACS